BDCA-2 hFc Chimera, Cynomolgus
BDCA-2 HFc Chimera, Cynomolgus

Immobilized BDCA-2 hFc Chimera, Cynomolgus, hFc Tag at 0.5 μg /ml (100 μl /well) on the plate. Dose response curve for Biotinylated Anti-BDCA-2 Antibody, hFc Tag with the EC50 of 15.5ng/ml determined by ELISA.

BDCA-2 HFc Chimera, Cynomolgus

The purity of BDCA-2 hFc Chimera, Cynomolgus is greater than 95% as determined by SEC-HPLC.

BDCA-2 HFc Chimera, Cynomolgus

BDCA-2 hFc Chimera, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

BDCA-2 hFc Chimera, Cynomolgus

BDCA-2, BDCA-3, and BDCA-4. In blood, BDCA-2 and BDCA-4 are expressed on CD11c(-) CD123(bright) plasmacytoid dendritic cells, whereas BDCA-3 is expressed on small population of CD11c() CD123(-) dendritic cells. All three Ags are not detectable on a third blood dendritic cell population, which is CD1c() CD11c(bright) CD123(dim), or on any other cells in blood.BDCA-2 is completely down-regulated on plasmacytoid CD11c(-) CD123(bright) dendritic cells, BDCA-2 is rapidly internalized at 37 degrees C after mAb labeling.
Z04749
¥72,752.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
hFc BDCA-2 (Tyr48-Ile212)
Accession # A0A2K5UWP4
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 44.99 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 53-63 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • BDCA-2 HFc Chimera, Cynomolgus
    • BDCA-2 HFc Chimera, Cynomolgus

    Immobilized BDCA-2 hFc Chimera, Cynomolgus, hFc Tag at 0.5 μg /ml (100 μl /well) on the plate. Dose response curve for Biotinylated Anti-BDCA-2 Antibody, hFc Tag with the EC50 of 15.5ng/ml determined by ELISA.

  • BDCA-2 HFc Chimera, Cynomolgus
    • BDCA-2 HFc Chimera, Cynomolgus

    The purity of BDCA-2 hFc Chimera, Cynomolgus is greater than 95% as determined by SEC-HPLC.

  • BDCA-2 HFc Chimera, Cynomolgus
    • BDCA-2 HFc Chimera, Cynomolgus

    BDCA-2 hFc Chimera, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background BDCA-2, BDCA-3, and BDCA-4. In blood, BDCA-2 and BDCA-4 are expressed on CD11c(-) CD123(bright) plasmacytoid dendritic cells, whereas BDCA-3 is expressed on small population of CD11c() CD123(-) dendritic cells. All three Ags are not detectable on a third blood dendritic cell population, which is CD1c() CD11c(bright) CD123(dim), or on any other cells in blood.BDCA-2 is completely down-regulated on plasmacytoid CD11c(-) CD123(bright) dendritic cells, BDCA-2 is rapidly internalized at 37 degrees C after mAb labeling.
Synonyms BDCA-2; BDCA2; CLECSF11; CLECSF7; DLEC; HECL; CLEC4C; CD303; CD303; DLEC;

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.